Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
And don't forget Tysabri (ELN) bp
Again thank you Jesse, do we have any way of checking the effects of antithrombin on the PAR-1 receptor? When then mentioned "meds" in the article, technically I wonder if AT III would be considered a med since it is a naturally occuring substance. Regards, bp
I was concerned by this comment about GTCBs own potential sales force clearly aimed at "pressuring" prospective partner(s). On the "Desperado Quotient" I give it a 6 on a scale of 10. Dr. Cox is a class act and didn't need to do that. I could see a comment like that designed to pressure one potential negiotator but if there were more than one why not play one off the other rather than threaten to "go it alone". We know where that has led before...bp
Thank you Jesse, But why would the authors not even speculate on the effect of antithrombin or test it to support their findings? regards, bp
Dew, Dr. Cox made mention of a letter in Nature re inflamatory nature of DIC, is this referenced in the RMF section? Also I thought your questions were great. Can you speculate on the following: one of the authors of the letter (or article) was from Scripps the other from J and J I believe. Interesting that this info should be dropped during the call. One wonders what the impact of recognition of the importance of AT III by a J and J scientist (if I did not misunderstand) might have on J and J being acutely aware of this product and in active negotiations. Now that would be a good thing. bp
MTB, Glad I have company. Doesn't look like too many others signing on. Interesting that some of the .87 cent recent sales went to LEO and LFB. Oh, and rabbits (or pigs) or our goats are not likely to get scraphe. bp
Get over it. Dew and Flo have done a great job of keeping us informed. I'm sure they are just as shaken by the stock price as we are but they are not here to hold our hands, nor to justify their or your decisions. Make your own decisions. As far as I am concerned we still transfuse blood and plasma products. Some donors have AIDS, Chagas disease, syphilis, hepatitis etc. They are screened out and the blood supply is considered safe. The GTCB goats are "approved" by the FDA and plenty of forethought has gone into keeping the herd safe. Tufts Vets have been involved as I remember as well. You can be sure the current situation is being followed closely and I fully expect some comments by Dr. Cox regarding the safety of the herd and the purification process which seems to be held to a much higher process than that of the screening process applied to our blood supply which certainly is not subjected to any "purification process". The future (follow ons, blood factors, mono clonals bioterrorism threats need our goats.) And that's the way it is. The rest is commentary. I'll bet Dew is buying here. He is a man of steel. I plan to buy a few thousand to keep him company. bp
Hmmmm, good point, thanks.
Jesse, They admit enrollment is slower than anticipated so I don't know about your timeline. Maybe the stock offering was to bring on more sites faster since the money clock is ticking and DIC indication is very important to GTCB.
Does anyone know how or why Genzyme acquired this right? Did it date back to GTCBs buy back of its own stock from Genz to grant it less power and take back the right of self determination? There has been quite a bit of history as GTCB has fought for independence, the brave little engine that could, as it were. It might not be such a bad thing to still look sexy to Genzyme but I still can't believe GTCB that many more companies trying to get on the dance card. bp
Jesse, What failed partnership? I don't think I saw anything to suggest partnership arrangements have failed. They have been delayed, that's for sure. The recent "fund raiser" at GTCB, I agree might be a statement they plan to hold on for the right deal and won't be pressured to take a low ball. Maybe it's just a matter of survival until the next administration which is sure to be more transgenic friendly. Regards, bp
To Flu, Aren't we "Dew" for an update from your friends at Merrimack? bp
Re Phase II, Don't think we should get our hopes up re timely completion. Multiple hints dropped in presentations that enrollement was not as speedy as expected. When is it ever. bp
Another monoclonal bites the dust--"Takeda phara cancels developement of matuzumab"--hope this wasn't one considered by GTCB for external contract. bp
I miss typed, epsilon amino caproic acid is a procoagulant not an anticoagulant. bp
Dew, Is there a significance to the red vs. the gold bars on this graphic? bp
Not too clearly stated as I re read this. Sorry. I am trying to get at timeline for comercial sales once 2009 INDs accepted. BTW, Did anyone catch 60 minutes tonight? There was a feature about Bayer and multiple patient deaths attributed to Epsilon amino caproic acid (I may not have the product exactly right) as a post operative anticoagulant used post CABG. Bayer did not look too good. One wonders if Bayer was a potential partner for GTCB whether the gray beards thought to wait until this data was scrutinized and in the public domain. Probably has absolutely no bearing on anything but thought I would mention it anyway as it might have bearing on FDA approval processes or be possibly helpful like the recent heparin problems re Baxter, in that Atryn is pure to 1 part PER was it billion with absolutely no evidence for antibody induction? best to all, bp
Dew, While we are on the subject, based on presumed acceptance of ATRYN by FDA, what kind of timeline for the 2009 IND's would you think? (Assuming we still have operating funds...) Thanks, bp
Three INDs for "09 thats impressive. That will be our year. Patience continues....bp
St. A--If so why not just get a loan? We've got the collateral in IP, land, future milestones, potential partners etc.??? This is a serious question that maybe you can address as a CFO. Would not a loan be better for the existing stockholders? Why not allow the existing stockholders the opportunty to obtain warrents too while they are at it...Regards and hope to all, bp
I believe "Mr." Jessie Livermore is an MD. I also think I might lay claim to the longevity claim, 1st posts and buys 1994 or 1995 with litte or no sales since (it could be said with some level of certaintly that I ain't too smart. biopearl (bp) Lets see what tomorrow brings!
Jessie, I too was blown away by this news only it happened to me about 3 years ago when they announced it. It was reminescent of the Lonza announcement which of course was followed by silence. Just like the Malaria press releases. We hear about what is happening or about to happen but never when it goes on hold or just dissapears. So who knows? bp
Dew, A plastic surgeon is an artist who reconstructs and earned the right to do so. Surgical residency is the toughest or at least was before these idiot rules that only allow an 80 hr work week. We did our best learning at night during internal medicine residency and various cardiology fellowships. But we still didn't work as hard as the surgeons. The derm boys did an internship usually at a pretty easy place and then goodby, no more night call. On to the world of rashes warts zits and now botox. There is a difference, size matters. bp
Jesse and mabgoat, VERY interesting patent app noted by our loyal flo with his usual service extrodinare for our board. WOW. This is what Judah (who unfortunately recently died) was talking about all along and what made for the (now defunct) partnership with GENZ which GTCB "bought back" the rights to lo those many years ago. I'm buying more. Regards, bp
Point taken, Dew, Thanks bp
Surely the partnership has already been negotiated contingent on the outcome of the nearly completed trial and given the guidance from GTCB will precede FDA approval. (Given a positive study of course!) bp
And we're talking ORAL replacement therapy not just IV. bp
Nor I, I just think that acceptance of this ground breaking technology will be easier for much of our society to accept, at least at first, if it uses DNA that is non human (e.g.synthetic) to make the transgene. Nonetheless, the realization that CPR saved lives eventually over rode the concerns of those who felt they could devine God's will. May the force of the twidle factor increase. Regards, bp
When the concept of CPR was introduced it was opposed by many because it opposed God's will. bp
Thank you biotechguy, This is what I was looking for in that "when" Atryn approved, if DNA for transgene is synthetic, "close enough" or even better (ADCC)than the human form, (and not immunogenic) perhaps public opinion will be far more favorable than if the DNA material were taken from a human source, even though potential for exact protein match is more probable. Don't you think the public should love this in the face of the stem cell division (sic) currently faced by our society? bp
Where does the transgene come from? Thanks bp
Follow on question (albeit not phrased as a question): I doubt the public would object to pampered goats in contrast to all those Chinese Hamsters who "donated" their ovaries to other companies. The public relations aspect to acceptance of our goats might make for an interesting discussion. bp
Dew, In terms of public acceptance of transgenically produced drugs, regarding the original snippet of DNA introduced into the process: Is that derived from a human cell or is it "constructed" in the lab? If the later, then possibly we will see emphasis on this to facilitate general acceptance of the manufacturing process or if the former what then with the nay sayers?? Thanks, bp
Flo, last I heard from our local Rheumatologist, 7 patient locally had been placed in study and they were amongst the largest contributors so I doubt the study is complete. bp
Ah yes, I remember it well and so does my wallet. What wallet.
Jesse, Dew has done it again. The research we were discussing is outlined in a 1999 article that outlines Dr. Volkman's work and the potential ties to Genzyme and Entremed as well as the fragment of ATIII they were looking at (presumably made by our goats). Anyway looks like it was eventually a non starter but the issue of inhibition of tumor neovascularization was mentioned. Check out the auxillary articles Dew recently listed and look at the last one under "cancer". Regards, bp
Well boys, Add one more to the list. As an "older" physician (cardiologist) I have also been in since the beginning and basically never sold. I remain a believer. (or perchance a fool, time will tell). Also had Genzyme Tissue Reparir and the Genzyme oncology spin off. That was sure fun. GTCB is my largest holding and I have continued to add. Love the science and the company's ability to make vast quantities of therapeutic proteins. Was particulary struck by the ability to make human albumin in cows since this represented such a large market and dealt so well with the potential for contaminants (were prions the fear here?) anyway this went nowhere to my knowlege. I thought the use of ATIII in heparin resistance and potential to make TPA via transgenics would come to fruition. Now the The hope for an oral Rx for hemophelia, production of pure Mabs, coag factors, A1AT and more of course represent such basic needs in medicine that I remain astounded by the lack of recognition this company has received. I keep buying. I admire Dew's fine work in educating us all. I was always curious about the details of the work by Dr. Judah Volkman many years ago (or was it with Entremed?) that I think may have spurred the partnership with Genzyme and GTCB re AT III (not positive it was Dr. Volkman,) as an inhibitor of neovascularization in tumors. Anyone know what ever happened there? That news (a long time past) spurred the stock price tremendously. Best wishes to all. bp
Thanks, Dew. bp
Re Pharming and fibrinogen. Pharming recently received orphan status for its recombinant fibrinogen, ? made in animal milk? the press release was quite short on details. Any idea how this compares or competes with ProGenetics? bp
As its going to rest (the thread that is...) consider this. Hard working guys like Jack Greenberg, the familiar voice of what, well many years anyway, who I suspect is from a fairly modest background (read: earns his money and didn't get a huge trust fund somewhere,) probably doesn't make nearly the salary of some of the voices on this board who keep telling us how many zillions of shares they own. I too work for it and have not been a particularly sucessful stock picker. So I will continue to work for it. (My problem, not yours--lets hope GTCB will be the exception!). That aside, my point is that given Jack's (and other's at GTCB, relative to some of your) salaries, buying 1500 shares is probably a big deal especially living in Massachusetts and maybe (I don't know this) having kids in college etc. My opinion is that it tells us he's in the game and working hard for us and believes in his company. He knows that he will get major recognition from bonuses, options, raises etc., when things get rolling and he is in a position to know. So he didn't have to buy the 1500 shares, he just did. Same for the others who have invested brain power, heart and soul into this project. Now to rest!!!! Happy holidays, bp